Egis: 11% sales increase in 2008/2009 financial year
2010-02-23
In the 2008/2009 financial year (i.e., ended 30 September 2009),
Egis, the Hungarian drug manufacturer, managed to achieve a 10.7% y-o-y increase of net sales revenues to HUF 106.3bn (€393.2m). The company’s net profit declined by 6% and reached HUF 13.13bn (€48.6m).
Most of the revenues - 72% - were derived from international sales accounting for HUF 74.4bn (€275.2m). This represented a 14.7% y-o-y increase. There was an aggregated boost of 24% of the sales in Russia, which is the largest export market for Egis, and other Commonwealth of Independent State (CIS) countries, and 13% in Eastern Europe. The Western Europe sales of finished products went up by 63%, but the API revenue fell by 28%.
The rest, 28% of the Egis revenues amounting to HUF 29.77bn (€110m), came from the sales in Hungary. The domestic sales increased by 1.4% year on year. According to IMS, Egis was placed fifth amongst the Hungarian drug manufacturers with a market share of 5.3% in sales value and 9.9% in volume.
PMR Online Access
Browse and search in our archive »
Subscribe to PMR RSS NEWS channels » 
